Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) have earned an average rating of “Moderate Buy” from the ten research firms that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, three have issued a hold rating, five have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $23.00.

A number of brokerages recently issued reports on ARCT. Weiss Ratings reissued a “sell (d-)” rating on shares of Arcturus Therapeutics in a report on Friday, July 17th. Roth Capital reaffirmed a “buy” rating and set a $41.00 target price on shares of Arcturus Therapeutics in a research note on Wednesday, September 2nd. Finally, Wall Street Zen upgraded shares of Arcturus Therapeutics from a “strong sell” rating to a “sell” rating in a report on Sunday, August 9th.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. BlackRock Inc. acquired a new position in Arcturus Therapeutics in the second quarter valued at approximately $17,566,000. ARK Investment Management LLC increased its stake in Arcturus Therapeutics by 39.4% during the fourth quarter. ARK Investment Management LLC now owns 2,611,099 shares of the biotechnology company’s stock worth $16,006,000 after acquiring an additional 738,378 shares during the last quarter. Amova Asset Management Americas Inc. increased its stake in Arcturus Therapeutics by 12.9% during the first quarter. Amova Asset Management Americas Inc. now owns 2,288,935 shares of the biotechnology company’s stock worth $17,648,000 after acquiring an additional 262,347 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. raised its position in Arcturus Therapeutics by 12.9% in the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,288,935 shares of the biotechnology company’s stock valued at $17,671,000 after purchasing an additional 262,347 shares during the period. Finally, Vanguard Group Inc. raised its position in Arcturus Therapeutics by 4.2% in the third quarter. Vanguard Group Inc. now owns 1,885,605 shares of the biotechnology company’s stock valued at $34,752,000 after purchasing an additional 75,440 shares during the period. 94.54% of the stock is currently owned by institutional investors and hedge funds.

Arcturus Therapeutics Stock Performance

NASDAQ ARCT opened at $13.98 on Friday. The stock’s fifty day moving average is $9.42 and its two-hundred day moving average is $8.28. The firm has a market capitalization of $397.31 million, a P/E ratio of -4.22 and a beta of 2.48. Arcturus Therapeutics has a fifty-two week low of $5.50 and a fifty-two week high of $24.17.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its earnings results on Friday, August 7th. The biotechnology company reported ($0.84) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.00) by $0.16. Arcturus Therapeutics had a negative return on equity of 46.54% and a negative net margin of 317.62%.The business had revenue of $2.96 million during the quarter, compared to the consensus estimate of $3.11 million. As a group, sell-side analysts forecast that Arcturus Therapeutics will post -3.21 EPS for the current year.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.